163 related articles for article (PubMed ID: 35712858)
1. S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia.
Thomas K; Germain M; Loch MM
J Investig Med High Impact Case Rep; 2022; 10():23247096221105249. PubMed ID: 35712858
[TBL] [Abstract][Full Text] [Related]
2. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
Jain S; Shah AN; Santa-Maria CA; Siziopikou K; Rademaker A; Helenowski I; Cristofanilli M; Gradishar WJ
Breast Cancer Res Treat; 2018 Sep; 171(2):371-381. PubMed ID: 29850984
[TBL] [Abstract][Full Text] [Related]
5. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
6. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
7. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
8. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
Shen S; Chen Y; Carpio A; Chang C; Iyengar NM
Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730
[TBL] [Abstract][Full Text] [Related]
9. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Abufaied M; Jumbo U; Alqalalwah A; Hamad MK
Cureus; 2021 Nov; 13(11):e19441. PubMed ID: 34909343
[TBL] [Abstract][Full Text] [Related]
10. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
[TBL] [Abstract][Full Text] [Related]
11. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
Blow T; Hyde PN; Falcone JN; Neinstein A; Vasan N; Chitkara R; Hurd MA; Sardesai S; Lustberg MB; Flory JH; Volek JS; Goncalves MD
Integr Cancer Ther; 2021; 20():15347354211032283. PubMed ID: 34259084
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose cotransporter-2 inhibitors for hypergycemia in phosphoinositide 3-kinase pathway inhibition.
Weintraub MA; Liu D; DeMatteo R; Goncalves MD; Flory JH
Breast Cancer Res Treat; 2024 Jan; 203(1):85-93. PubMed ID: 37704834
[TBL] [Abstract][Full Text] [Related]
13. Diabetic Ketoacidosis With the Use of Alpelisib in a Patient With Metastatic Breast Cancer Without Diabetes.
Polisetty L; Teresa Selvin S; Tan JW
JCEM Case Rep; 2024 Apr; 2(4):luae023. PubMed ID: 38524964
[TBL] [Abstract][Full Text] [Related]
14. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
16. Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Carrillo M; Rodriguez RM; Walsh CL; Mcgarvey M
AACE Clin Case Rep; 2021; 7(2):127-131. PubMed ID: 34095470
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
[No Abstract] [Full Text] [Related]
18. Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.
Schutte T; Zeverijn LJ; Geurts BS; de Wit GF; Kok M; Opdam FL
Oncologist; 2023 Jul; 28(7):e493-e497. PubMed ID: 37086483
[TBL] [Abstract][Full Text] [Related]
19. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract][Full Text] [Related]
20. Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations.
Pla Peris B; Arranz Martin A; Ballesteros García A; Sebastián-Valles F; Marazuela Azpiroz M
Front Endocrinol (Lausanne); 2022; 13():802612. PubMed ID: 35178031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]